Increasing the Odds of: "Is this Treatment Going to Work?"
Until 1997, when US FDA approved the first molecular-targeted drug, rituximab (a monoclonal antibody against CD20, used in the treatment of CD20 positive B-cell lymphoma), the main systemic treatments for advanced cancer were a handful of chemotherapy agents. Today, more than 800 anticancer drugs are in active development. As the armamentarium grows, the decision process on the most appropriate drug selection becomes more difficult, unless we have some biomarkers that are predictive of efficacy, and, preferably, also of toxicity.
Many of the "newer" drugs are targeted agents, developed by screening for inhibitors of particular components that drive the signalling pathways in carcinogenesis. It is becoming clear that the use of biomarkers, to identify which patient is likely to respond to a drug on the basis of tumour profile, has benefit. One example of this is illustrated by the predictive value of EGFR (epidermal growth factor receptor) mutational status in the selection of patients with non-small cell lung cancer (NSCLC) for gefitinib and erlotinib, the tyrosine kinase inhibitors (TKIs) that target EGFR.
NSCLC accounts for 75% of all lung cancer, the most common cause of cancer death worldwide. It has been known for some time that EGFR is overexpressed in NSCLC 1 . EGFR is a transmembrane protein that is involved in cell growth and proliferation when activated.
Mutation of the EGFR gene causes constitutive activation of EGFR, and is seen commonly in the Asian population. In one Japanese study, EGFR mutations were found to be present in 40% of lung cancer 2 . Tyrosine kinase inhibitors interfere with the function of EGFR by blocking its intracellular ATP-binding domain to prevent phosphorylation, thus transduction of the signal cascade for growth and proliferation is inhibited.
When early clinical trials were being carried out, specific targets of tyrosine kinase inhibitors were not known, and patients were not selected. The results of these trials showed that erlotinib and gefitinib were non-inferior to, but not better than, standard chemotherapy 3 . However, subgroup analysis revealed that the response rate to TKIs was higher among Asians, women, patients with adenocarcinoma and non-smokers 4, 5 This is a relevant finding in Singapore, where adenocarcinoma accounts for about 43% of diagnosed lung cancer cases 6 , and 70% of these are in non-smokers 7 . Initially, these characteristics were taken into consideration in the selection of patients for TKIs.
Later, correlation between EGFR mutations and response to gefitinib and erlotinib was demonstrated 8 . The realisation that predicting EGFR mutation status could result in higher response rate to TKIs has made a marked difference. Although the presence of EGFR mutation and lack of response to EGFR tyrosine kinase inhibitors (TKIs) is observed, the overall response rate of these drugs in selected patients is impressive. One prospective clinical trial demonstrated that patients with known EGFR mutation had a response rate of 73.7% on gefitinib, compared to 30.7% on carboplatin and paclitaxel chemotherapy (one of the standard regimens for lung cancer). Progression free survival was also longer (10.8 months v 5.4 months in favour of gefitinib) 9 .
In current practice, patients with adenocarcinoma of the lung are routinely tested for EGFR mutation. Recommendation of EGFR TKIs is made on the basis of a positive result. With the cancer genome fully sequenced 10 , it is hoped that there will be increasing availability of appropriate, validated biomarkers to select patients for therapy in the clinical setting.
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